Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sinovac PCV24 in children aged 2 months to 5 years
NCT07300644Phase 2Recruiting
- Sponsor
- Sinovac Life Sciences
- Start
- Nov 2025
- Primary completion
- Sep 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Sinovac PCV24 in pneumococcal infection (2 arms), sponsored by Sinovac Life Sciences. Primary endpoints: Pneumococcal serotype-specific IgG antibody geometric mean concentration and Incidence of adverse reactions. Started Nov 2025; status: recruiting.
02
Drugs
Sinovac PCV24
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT07300644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07300644.